Tom Daniel

Tom Daniel was President, Global Research and Early Development at Celgene Corporation over the last decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation. Tom previously served as director at Epizyme, Juno, Sana Therapeutics, and VIR Bio. He is currently Chairman at Locana and serves as director at Vividion Therapeutics, Gossamer Bio, Magenta Therapeutics, and Zafgen, Inc. He is a Trustee of Reed College, chairs the Board of Overseers of The Scripps Research Institute, serves on the Board of the Alliance for Lupus Research, on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, and is a senior advisor to several private biotechnology companies. A nephrologist and former academic investigator, Tom was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt. Dr. Daniel earned his medical degree from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed his residency in Internal Medicine at Massachusetts General Hospital.